- Company
- Sanofi & 4 other companies will participate in NIP
- by Lee, Tak-Sun Jun 10, 2022 05:42am
- Unlike the previous year, Sanofi Pasteur is expected to participate as a new business operator and Ilyang Pharmaceutical is expected to be excluded. As a result of the bidding conducted through the Nara Market of the Public Procurement Service on the 9th, Sanofi Pasteur was selected as the first choice by writing the lowest price of 14,433
- Company
- Hanmi’s new biologic receives orphan designation in Europe
- by Chon, Seung-Hyun Jun 10, 2022 05:42am
- New drug products being developed by Hanmi Pharmaceutical have received a total of 20 orphan drug designations from regulatory authorities in Korea and abroad. Hanmi Pharmaceutical announced on the 9th that the European Medicines Agency granted an orphan drug designation for its new triple action biologic drug LAPS Triple Agonist (HM15211)
- Company
- Jeil and Amgen agree to co-sell PCSK9 inhibitor Repatha
- by Nho, Byung Chul Jun 10, 2022 05:42am
- Jeil Pharmaceutical (CEO Seong Seok-je) and Amgen Korea (CEO Noh Sang-kyung) announced on the 7th that they signed a joint sales contract for Repatha for patients with atherosclerosis cardiovascular disease and hypercholesterolemia as of the 1st of this month. With this joint sales contract, Jeil Pharmaceutical and Amgen Korea will conduct
- Policy
- Govt skeptical about using existing vaccines on monkeypox
- by Lee, Jeong-Hwan Jun 9, 2022 06:25am
- The government has said that the use of licensed human smallpox vaccines, antivirals, or vaccinia immune globulin intravenous (VIGIV) to prevent the domestic outbreak of monkeypox should be carefully considered in terms of efficacy and safety. In particular, the authorities explained there is a plan to study whether the 3rd generation sma
- Policy
- Cases for Pre-approval of Ultomiris exceeds 100
- by Lee, Tak-Sun Jun 9, 2022 06:25am
- The number of approved Ultomiris administered was 101 until April. Ultomiris, a treatment for paroxysmal nocturnal hemoglobinuria (PNH), has been shown to have completely replaced Soliris, the existing treatment since its benefits in June last year. Both are expensive rare drugs, and must be approved in advance by the Board of Review
- Policy
- Monkeypox becomes Class 2 infectious disease in Korea
- by Lee, Jeong-Hwan Jun 9, 2022 06:24am
- The viral zoonosis monkeypox will be designated and managed as a ‘Class 2 infectious disease’ by law starting today (8th). With its level raised, monkeypox will now be managed and considered to have the same level of risk as COVID-19, tuberculosis, and chickenpox. If a person is confirmed with a Class 2 infectious disease, this mus
- Policy
- Evusheld is expected to be introduced this month
- by Lee, Jeong-Hwan Jun 9, 2022 06:24am
- The government is expected to introduce Evusheld, a COVID-19 antibody treatment that is administered to patients who do not form antibodies well even with vaccinations, to Korea this month. Lee Ki-il, the first general coordinator of the Central Disaster and Safety Countermeasures Headquarters, presided over a meeting at the Sejong Governm
- Company
- Genomictree's colorectal cancer business is booming
- by Lee, Seok-Jun Jun 9, 2022 06:23am
- FS Research highly evaluated Genomictree's growth potential in a report on the 8th. Genomictree is a company that discovers biomarkers, verifies clinical efficacy, and develops and sells early diagnosis products for various cancers (colonial cancer, lung cancer, bladder cancer, etc.). According to the report, sales of Genomictree's colorec
- Company
- Impurity data on schizophrenia and asthma drugs submitted
- by Chon, Seung-Hyun Jun 8, 2022 05:56am
- Pharmaceutical companies are submitting results of their impurity inspections on the schizophrenia treatment ‘Quetiapine’ and asthma and allergic rhinitis treatment ‘Montelukast’ one after another. As of now, no product has been recalled due to excessive impurities, and the health authorities plan to take follow-up measures after reviewi
- Opinion
- [Reporter's view]Will arbitrary manufacturing be eradicated?
- by Kim, Jin-Gu Jun 8, 2022 05:56am
- A revision to the Pharmaceutical Affairs Act, which allows the imposition of "punitive fines" on pharmaceutical companies that violate GMPs, passed the National Assembly. It also included canceling the judgment of suitability for the GMP if a violation is found, and allowing a prison term of up to five years or a fine of up to 50 million won,
